Artwork

コンテンツは Sam Parnell & Ivanna Rosendal, Sam Parnell, and Ivanna Rosendal によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Sam Parnell & Ivanna Rosendal, Sam Parnell, and Ivanna Rosendal またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!

Kimberly Tableman: Does true transformation in trials start with the clinical protocol?

44:17
 
シェア
 

Manage episode 382347597 series 3526489
コンテンツは Sam Parnell & Ivanna Rosendal, Sam Parnell, and Ivanna Rosendal によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Sam Parnell & Ivanna Rosendal, Sam Parnell, and Ivanna Rosendal またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal

Send us a text

This week we are hosting Kimberly Tableman, Founder and CEO of ESPERO Health, and speak about how clinical trial protocols are being re-imagined in our industry. We dive into what a protocol actually is and what it describes.

Protocols are currently being developed with a lot of manual research. WIth googling, phoning friends and re-using existing protocols in word documents.

Trials today are being conducted in a more complex environment than before. This means that it is necessary to adapt the trial design as the trial is executed. Creating a trial and executing it unchanged is becoming more rare and requirements for additional digitization in this space are increasing.

Trial design is also a very collaborative process involving 10-12 stakeholders. Using a system that supports collaborative creation is key to avoid the pitfalls of versioning and overwriting of comments.

Writing the protocol with data collected from the current market can make the protocol more robust and accelerate timelines. That is what Espiro health aims to provide in their protocol platform. Making it easy is the trick to ensure adoption.

We also speak about the dynamics that lead to rigidity in the pharmaceutical space and how having sufficient inflow of money in especially big pharma leads to containing the status quo.

Speaking out of her experience as a founder, we dive into what it means to start a technology company in the life sciences space and how funding is key to getting off the ground.

Guest:

Kimberly Tableman

https://www.linkedin.com/in/kimberly-tableman/

ESPERO Health

https://www.linkedin.com/company/espero-health/

________
Reach out to Sam Parnell and Ivanna Rosendal
Join the conversation on our LinkedIn page

  continue reading

67 つのエピソード

Artwork
iconシェア
 
Manage episode 382347597 series 3526489
コンテンツは Sam Parnell & Ivanna Rosendal, Sam Parnell, and Ivanna Rosendal によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Sam Parnell & Ivanna Rosendal, Sam Parnell, and Ivanna Rosendal またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal

Send us a text

This week we are hosting Kimberly Tableman, Founder and CEO of ESPERO Health, and speak about how clinical trial protocols are being re-imagined in our industry. We dive into what a protocol actually is and what it describes.

Protocols are currently being developed with a lot of manual research. WIth googling, phoning friends and re-using existing protocols in word documents.

Trials today are being conducted in a more complex environment than before. This means that it is necessary to adapt the trial design as the trial is executed. Creating a trial and executing it unchanged is becoming more rare and requirements for additional digitization in this space are increasing.

Trial design is also a very collaborative process involving 10-12 stakeholders. Using a system that supports collaborative creation is key to avoid the pitfalls of versioning and overwriting of comments.

Writing the protocol with data collected from the current market can make the protocol more robust and accelerate timelines. That is what Espiro health aims to provide in their protocol platform. Making it easy is the trick to ensure adoption.

We also speak about the dynamics that lead to rigidity in the pharmaceutical space and how having sufficient inflow of money in especially big pharma leads to containing the status quo.

Speaking out of her experience as a founder, we dive into what it means to start a technology company in the life sciences space and how funding is key to getting off the ground.

Guest:

Kimberly Tableman

https://www.linkedin.com/in/kimberly-tableman/

ESPERO Health

https://www.linkedin.com/company/espero-health/

________
Reach out to Sam Parnell and Ivanna Rosendal
Join the conversation on our LinkedIn page

  continue reading

67 つのエピソード

Kaikki jaksot

×
 
Loading …

プレーヤーFMへようこそ!

Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。

 

クイックリファレンスガイド